A Phase II study of ofatumumab has shown positive interim results for safety and pharmacokinetics in patients with relapsing-remitting multiple sclerosis (RRMS).
Ofatumumab is a novel human monoclonal antibody to treat multiple sclerosis, and is being developed by Genmab in collaboration with GlaxoSmithKline.
The 48-week study randomised 38 patients with RRMS to evaluate the safety of three doses of ofatumumab and assess its efficacy.
The drug demonstrated statistically significant reductions in the number of brain lesions in all its dose groups compared to a placebo.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData